Docetaxel nanopolymer - Pfizer

Drug Profile

Docetaxel nanopolymer - Pfizer

Alternative Names: BIND-014

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University; Yale University
  • Developer BIND Therapeutics; Pfizer
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-small cell lung cancer

Highest Development Phases

  • Phase II Cervical cancer; Cholangiocarcinoma; Head and neck cancer; Non-small cell lung cancer; Urogenital cancer
  • No development reported Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)
  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
  • 13 Apr 2016 BIND Therapeutics terminates the iNSITE2 trial in Urogenital cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) and Cholangiocarcinoma (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA and Russia (IV) (NCT02479178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top